Aging itself holds clues to treating obesity and disease
In the crowded arena of metabolic medicine, BioAge Labs arrives with an unusual compass: the biology of human aging itself. The Emeryville-based biotech will present at a major New York healthcare conference in December, offering investors their clearest look yet at BGE-102, a drug candidate designed to quiet inflammatory pathways long associated with how bodies age and accumulate disease. With Phase 1 safety data expected before year's end, the company stands at one of those early thresholds where scientific premise must begin its long negotiation with clinical reality.
- The obesity drug race has grown crowded since GLP-1 therapies reshaped expectations, and BioAge is betting that targeting aging biology offers a path the blockbusters haven't taken.
- BGE-102's ability to cross the blood-brain barrier sets it apart technically, but Phase 1 trials mean the compound has only just begun proving itself in human bodies.
- Year-end safety data from the BGE-102 trial looms as the company's most immediate test — early numbers that will either validate or complicate the aging-biology thesis.
- The December 4 fireside chat and accompanying one-on-one investor meetings signal that BioAge is actively courting the partnerships and capital that clinical-stage companies need to survive the long road ahead.
- Preclinical APJ-receptor programs in both injectable and oral formats suggest the company is hedging its bets, building a pipeline rather than staking everything on a single mechanism.
BioAge Labs, a clinical-stage biotech trading on Nasdaq under BIOA, will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 4, 2025. CEO and co-founder Kristen Fortney and CFO Dov Goldstein will lead a fireside chat before meeting privately with investors — the quieter conversations where serious interest tends to take shape.
The company's central argument is that aging biology, not just caloric imbalance or genetics, underlies conditions like obesity and cardiovascular disease. Its lead candidate, BGE-102, is a small-molecule NLRP3 inhibitor that is orally available and capable of crossing the blood-brain barrier — a technical distinction that allows it to act within the central nervous system. A Phase 1 trial testing ascending doses is underway, with initial safety data expected by year-end.
Beyond BGE-102, BioAge is developing additional obesity treatments targeting the APJ receptor in both long-acting injectable and oral forms, though these remain in preclinical stages. The company's discovery platform draws on proprietary human longevity data — studying people who age well metabolically and working backward through the biology that enables it.
The presentation arrives as obesity treatment commands extraordinary attention in biotech, energized by the GLP-1 wave but still open to alternative mechanisms. For BioAge, the conference is both a market signal and a prelude: the BGE-102 safety data due before year's end will be the first real measure of whether the company's aging-centered thesis holds up in human trials.
BioAge Labs, a clinical-stage biotechnology company based in Emeryville, California, will take the stage at the Piper Sandler 37th Annual Healthcare Conference in New York next month to discuss its work on metabolic diseases through the lens of human aging biology. The company, which trades on the Nasdaq under the ticker BIOA, has built its pipeline around a simple but ambitious premise: that the aging process itself holds clues to treating conditions like obesity and cardiovascular disease.
The presentation is scheduled for December 4, 2025, in the form of a fireside chat running from 1:30 to 1:55 p.m. Eastern time. Kristen Fortney, the company's CEO and co-founder, will appear alongside Dov Goldstein, the chief financial officer and a physician, to walk investors and conference attendees through the company's strategy and progress. Beyond the formal presentation, both executives will participate in one-on-one meetings with interested parties—a standard practice at these conferences where the real deal-making often happens in smaller rooms.
At the center of BioAge's clinical work sits BGE-102, a small-molecule drug candidate designed to inhibit NLRP3, a protein involved in inflammatory pathways. The compound is orally available and can cross the blood-brain barrier, a significant technical achievement that allows it to work in the central nervous system. The company is testing it for obesity and cardiovascular risk factors. A Phase 1 trial measuring both single and multiple ascending doses is currently underway, with initial safety data expected by the end of this year—a timeline that suggests the company is moving at a deliberate but steady pace through early-stage development.
Beyond BGE-102, BioAge is developing additional obesity treatments in two different formats: long-acting injectable versions and oral small molecules that target the APJ receptor, a different biological pathway. These programs remain in preclinical stages, meaning they have not yet entered human testing. The company's broader approach draws on what it calls a proprietary discovery platform built from human longevity data—essentially, insights gleaned from studying people who age well and remain metabolically healthy, then reverse-engineering the biology that makes that possible.
The conference appearance comes at a moment when obesity treatment has become one of the most closely watched areas in biotech and pharmaceuticals. The success of GLP-1 receptor agonists like semaglutide has reshaped the landscape, but it has also created space for companies pursuing different mechanisms. BioAge's focus on aging biology as a root cause of metabolic disease positions it in a distinct corner of that market. For investors, the presentation offers a chance to assess whether the company's science translates into clinical results—and whether the data emerging from the BGE-102 trial will support the company's thesis.
Investors and media who wish to follow the presentation can register for a live webcast. Recordings will be archived on the company's investor relations website for 30 days after the event, allowing those unable to attend in real time to catch up. For BioAge, the conference serves as both a milestone marker and a signal to the market that the company believes it has something worth showing. The initial safety data from BGE-102 expected by year-end will be the next critical moment to watch.
Citas Notables
BioAge is developing therapeutic candidates for metabolic diseases by targeting the biology of human aging— Company description
La Conversación del Hearth Otra perspectiva de la historia
Why does a company present at a conference like this? What's the actual goal?
It's partly about visibility with investors and analysts who cover the space, but it's also about credibility. When you're in early clinical trials, these presentations say: we're real, we're moving forward, and we have data coming. It's a way to build momentum before the data itself arrives.
So this is strategic timing—they're announcing the presentation before the Phase 1 data drops?
Exactly. They're saying the data is coming by year-end, and here's the team and the science behind it. It keeps the company in the conversation. If you wait until after the data, you've already missed the chance to shape expectations.
What makes BGE-102 different from the drugs already working for obesity?
It's a different target. The GLP-1 drugs work on appetite and glucose control. BGE-102 targets inflammation through NLRP3 inhibition. The theory is that chronic inflammation is part of why people gain weight and develop metabolic disease in the first place. If you can address that root cause, you might get a different kind of benefit.
Is that proven?
Not yet in humans. That's what the Phase 1 trial is for—to show it's safe and that it actually does what they think it does. The preclinical work suggests it works, but the human data will tell the real story.
Why does the company care so much about aging biology specifically?
Because aging is the biggest risk factor for metabolic disease. The older you get, the more likely you are to develop obesity, diabetes, heart disease. If you can understand and intervene in the aging process itself, you're not just treating a symptom—you're addressing the underlying mechanism. That's the bet.
And if it works?
Then you have a drug that could work for multiple conditions at once, because they all share that aging biology foundation. That's worth a lot more than a single-indication drug.